Segall Bryant & Hamill LLC Decreases Position in AngioDynamics, Inc. $ANGO

Segall Bryant & Hamill LLC cut its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 19.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 965,965 shares of the medical instruments supplier’s stock after selling 232,192 shares during the period. Segall Bryant & Hamill LLC’s holdings in AngioDynamics were worth $10,983,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. D.A. Davidson & CO. bought a new stake in shares of AngioDynamics in the 4th quarter valued at about $1,751,000. Weber Capital Management LLC ADV purchased a new stake in AngioDynamics during the 4th quarter valued at about $17,978,000. Armistice Capital LLC grew its position in AngioDynamics by 3.9% during the 4th quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock worth $21,828,000 after acquiring an additional 64,000 shares during the last quarter. Bastion Asset Management Inc. grew its position in AngioDynamics by 17.4% during the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock worth $14,107,000 after acquiring an additional 194,822 shares during the last quarter. Finally, Royce & Associates LP increased its stake in AngioDynamics by 27.3% in the 4th quarter. Royce & Associates LP now owns 1,267,451 shares of the medical instruments supplier’s stock worth $16,274,000 after purchasing an additional 272,091 shares during the period. 89.43% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, SVP Warren Nighan, Jr. sold 23,370 shares of AngioDynamics stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the sale, the senior vice president owned 64,745 shares in the company, valued at $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 6.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

ANGO has been the subject of several recent research reports. HC Wainwright boosted their price objective on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Zacks Research downgraded shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Canaccord Genuity Group upped their price target on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, AngioDynamics has a consensus rating of “Hold” and a consensus price target of $19.50.

AngioDynamics Price Performance

ANGO opened at $14.79 on Monday. AngioDynamics, Inc. has a one year low of $8.36 and a one year high of $15.19. The business has a 50 day simple moving average of $12.81 and a two-hundred day simple moving average of $11.51. The firm has a market capitalization of $611.27 million, a price-to-earnings ratio of -17.00 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The firm had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, sell-side analysts expect that AngioDynamics, Inc. will post -0.27 EPS for the current fiscal year.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.